Literature DB >> 2360828

Fluconazole levels in plasma and vaginal secretions of patients after a 150-milligram single oral dose and rate of eradication of infection in vaginal candidiasis.

E T Houang1, O Chappatte, D Byrne, P V Macrae, J E Thorpe.   

Abstract

Mean peak concentrations of fluconazole in plasma and vaginal secretions of females after a 150-mg single oral dose were shown to be 2.82 micrograms/ml and 2.43 micrograms/g, respectively. Our results indicate that clinically efficacious concentrations of fluconazole in vaginal secretions are easily achieved after this single oral dose.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2360828      PMCID: PMC171718          DOI: 10.1128/AAC.34.5.909

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  4 in total

1.  Gas chromatographic method for the determination of fluconazole, a novel antifungal agent, in human plasma and urine.

Authors:  P R Wood; M H Tarbit
Journal:  J Chromatogr       Date:  1986-11-28

2.  Single-dose oral fluconazole in the treatment of vaginal candidosis.

Authors:  K W Brammer; J M Feczko
Journal:  Ann N Y Acad Sci       Date:  1988       Impact factor: 5.691

3.  A comparison of fluconazole and ketoconazole in the oral treatment of vaginal candidiasis; report of a double-blind multicentre trial.

Authors:  E Kutzer; R Oittner; S Leodolter; K W Brammer
Journal:  Eur J Obstet Gynecol Reprod Biol       Date:  1988-12       Impact factor: 2.435

4.  Fluconazole in the management of oropharyngeal candidosis in a predominantly HIV antibody-positive group of patients.

Authors:  B Dupont; E Drouhet
Journal:  J Med Vet Mycol       Date:  1988-02
  4 in total
  21 in total

1.  Comparison of vaginal flora after treatment with a clotrimazole 500 mg vaginal pessary or a fluconazole 150 mg capsule for vaginal candidosis.

Authors:  F C Boag; E T Houang; R Westrom; S M McCormack; A G Lawrence
Journal:  Genitourin Med       Date:  1991-06

2.  Clinical pharmacokinetics of fluconazole in superficial and systemic mycoses.

Authors:  D Debruyne
Journal:  Clin Pharmacokinet       Date:  1997-07       Impact factor: 6.447

3.  Management of recurrent vulvovaginal candidiasis: unresolved issues.

Authors:  Jack D Sobel
Journal:  Curr Infect Dis Rep       Date:  2006-11       Impact factor: 3.725

4.  Efficacy of the clinical agent VT-1161 against fluconazole-sensitive and -resistant Candida albicans in a murine model of vaginal candidiasis.

Authors:  E P Garvey; W J Hoekstra; R J Schotzinger; J D Sobel; E A Lilly; P L Fidel
Journal:  Antimicrob Agents Chemother       Date:  2015-06-29       Impact factor: 5.191

Review 5.  Fluconazole. An update of its antimicrobial activity, pharmacokinetic properties, and therapeutic use in vaginal candidiasis.

Authors:  C M Perry; R Whittington; D McTavish
Journal:  Drugs       Date:  1995-06       Impact factor: 9.546

6.  Human subcutaneous tissue distribution of fluconazole: comparison of microdialysis and suction blister techniques.

Authors:  Lucy Sasongko; Kenneth M Williams; Richard O Day; Andrew J McLachlan
Journal:  Br J Clin Pharmacol       Date:  2003-11       Impact factor: 4.335

Review 7.  Clinical pharmacokinetics of fluconazole.

Authors:  D Debruyne; J P Ryckelynck
Journal:  Clin Pharmacokinet       Date:  1993-01       Impact factor: 6.447

8.  Comparing the Recurrence of Vulvovaginal Candidiasis in Patients Undergoing Prophylactic Treatment with Probiotic and Placebo During the 6 Months.

Authors:  Robab Davar; Fahimeh Nokhostin; Maryam Eftekhar; Leili Sekhavat; Mohammad Bashiri Zadeh; Farimah Shamsi
Journal:  Probiotics Antimicrob Proteins       Date:  2016-09       Impact factor: 4.609

Review 9.  Management of patients with recurrent vulvovaginal candidiasis.

Authors:  Jack D Sobel
Journal:  Drugs       Date:  2003       Impact factor: 9.546

10.  Fluconazole susceptibility of vaginal isolates obtained from women with complicated Candida vaginitis: clinical implications.

Authors:  J D Sobel; M Zervos; B D Reed; T Hooton; D Soper; P Nyirjesy; M W Heine; J Willems; H Panzer
Journal:  Antimicrob Agents Chemother       Date:  2003-01       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.